Mechanisms of Action of Metformin in Type 2 Diabetes and Associated Complications: An Overview

被引:76
作者
Correia, Sonia [1 ,2 ]
Carvalho, Cristina [2 ]
Santos, Maria S. [1 ,2 ]
Seica, Raquel [3 ,4 ]
Oliveira, Catarina R. [1 ,5 ]
Moreira, Paula I. [1 ,3 ]
机构
[1] Univ Coimbra, Ctr Neurosci & Cell Biol, P-3000354 Coimbra, Portugal
[2] Univ Coimbra, Fac Sci & Technol, Dept Zool, P-300354 Coimbra, Portugal
[3] Univ Coimbra, Fac Med, Inst Physiol, P-300354 Coimbra, Portugal
[4] Univ Coimbra, Biomed Inst Res Light & Image, P-300354 Coimbra, Portugal
[5] Univ Coimbra, Fac Med, Inst Biochem, P-300354 Coimbra, Portugal
关键词
AMP-activated protein kinase; brain protection; diabetes-associated complications; hyperglycemia; insulin resistance; metformin; type; 2; diabetes; vasculoprotection;
D O I
10.2174/138955708786369546
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Type 2 diabetes is a major health problem associated with excess mortality and morbidity. Vascular complications are one of the most serious consequences of this disorder. Moreover, type 2 diabetes is also a risk factor for cerebral complications, including cognitive impairment and dementia. However, it has been shown that tight glycemic control contributes to reduce the incidence of diabetes-associated complications. Metformin is a potent antihyperglycemic agent widely used in the management of type 2 diabetes whose main actions are the suppression of gluconeogenesis and the improvement of glucose uptake and insulin sensitivity. This review is mainly devoted to describe the mechanisms of action underlying the antidiabetic effects of metformin. Furthermore, we will present evidence for the protective effects of metformin against diabetes-associated complications mainly cerebral and vascular complications. Finally, we will describe the few known side effects associated to this antidiabetic agent.
引用
收藏
页码:1343 / 1354
页数:12
相关论文
共 180 条
[1]   Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus [J].
Abbasi, F ;
Chu, JW ;
McLaughlin, T ;
Lamendola, C ;
Leary, ET ;
Reaven, GM .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2004, 53 (02) :159-164
[2]   Results of a placebo-controlled study of the metabolic effects of the addition of metaformin to sulfonylurea-treated patients - Evidence for a central role of adipose tissue [J].
Abbasi, F ;
Kamath, V ;
Rizvi, AA ;
Carantoni, M ;
Chen, YDI ;
Reaven, GM .
DIABETES CARE, 1997, 20 (12) :1863-1869
[3]   Strategies to prevent type 2 diabetes [J].
Abuissa, H ;
Bell, DSH ;
O'Keefe, JH .
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (07) :1107-1114
[4]  
Ahmann AJ, 2007, AM J MANAG CARE, V13, pS41
[5]  
Ajjan Ramzi A, 2006, Diab Vasc Dis Res, V3, P147, DOI 10.3132/dvdr.2006.023
[6]   The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations [J].
Allen, KV ;
Frier, BM ;
Strachan, MWJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 490 (1-3) :169-175
[7]   Metformin-associated vitamin B12 deficiency [J].
Andrès, E ;
Noel, E ;
Goichot, B .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (19) :2251-2252
[8]  
[Anonymous], 2003, BR J DIABETES VASC D, DOI DOI 10.1177/14746514030030041501
[9]  
[Anonymous], COCHRANE DATABASE SY
[10]  
Arauz-Pacheco Carlos, 2004, Diabetes Care, V27 Suppl 1, pS65